Public Views on Whether the Use of Pharmaceutical Neuroenhancements Should Be Allowed

Medicine, Environmental and Public Health, Neurology, Pharmacy,
pharmaceutical neuroenhancements   public views   regulation   societal effects   individual effects  

Research Report on Whether the Public Should Be Allowed to Use Drug Enhancers Introduction In recent years, some individuals have started using drugs to enhance cognitive and socio-emotional functions and have requested off-label prescriptions from doctors for neuroenhancement (e.g., stimulants). However, discussions about whether such uses should ...

Amelioration of astrocyte-mediated neuroinflammation by EI-16004 confers neuroprotection in an MPTP-induced Parkinson’s disease model

Medicine, Neurology, Pharmacy, Life Sciences, Cell Biology, Biochemistry,
Parkinson’s disease   EI-16004   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine   neuroprotection   neuroinflammation   astrocyte  

Alleviating Effect of EI-16004 on Astrocyte-Mediated Neuroinflammation in MPTP-Induced Parkinson’s Disease Model Background Introduction Parkinson’s Disease (PD) is a neurodegenerative disorder primarily affecting the elderly, characterized by tremors, bradykinesia, rigidity, and loss of postural reflexes, mainly due to the loss of dopaminergic neu...

Dutch Pharmacogenetics Working Group (DPWG) Guideline for the Gene-Drug Interaction of CYP2C9, HLA-A, and HLA-B with Anti-epileptic Drugs

Medicine, Basic Medical Sciences, Neurology, Pharmacy, Life Sciences, Genetics,
pharmacogenetics   anti-epileptic drugs   CYP2C9   HLA-A   HLA-B   drug interactions   personalized medicine  

Dutch Pharmacogenetics Working Group Guideline for CYP2C9, HLA-A and HLA-B Gene-Drug Interactions with Antiepileptic Drugs Background Pharmacogenetics (PGx) studies how genetic variations affect individual drug responses, aiming to guide drug selection and dosing, optimize drug therapy, prevent adverse drug reactions, and achieve safer and more cos...

Clinical Impact of Preemptive Pharmacogenomic Testing on Antiplatelet Therapy in a Real-World Setting

Medicine, Infectious Diseases, Medical Laboratory Science, Neurology, Pharmacy, Cardiovascular System, Life Sciences, Immunology, Genetics,
pharmacogenomics   antiplatelet therapy   CYP2C19   acute coronary syndromes   percutaneous coronary interventions   clinical outcomes   healthcare utilization  

Clinical Impact of Pharmacogenomic Testing on Antiplatelet Therapy Background Pharmacogenomics (PGx) is changing the use of P2Y12 inhibitors (antiplatelet drugs), which are widely used in the treatment of acute coronary syndrome (ACS), neurovascular problems, and vascular diseases. Among them, clopidogrel is a commonly used P2Y12 inhibitor. This pr...

Epigallocatechin-3-Gallate Inhibits LPS/AβO-Induced Neuroinflammation in BV2 Cells Through Regulating the ROS/Txnip/NLRP3 Pathway

Medicine, Basic Medical Sciences, Neurology, Pharmacy, Life Sciences, Cell Biology, Biochemistry,
Alzheimer's Disease   Amyloid β   Epigallocatechin-3-Gallate   NLRP3 Inflammasome   Txnip  

Epigallocatechin-3-Gallate (EGCG) Inhibits Neuroinflammation in BV2 Cells by Regulating the ROS/TXNIP/NLRP3 Pathway Research Background Alzheimer’s Disease (AD) is a degenerative brain disorder primarily affecting the elderly, characterized by persistent cognitive dysfunction and behavioral impairment. The neuropathological changes in AD include β-...

β-sitosterol alleviates neuropathic pain by affecting microglia polarization through inhibiting tlr4/nf-κb signaling pathway

Medicine, Neurology, Pharmacy, Life Sciences, Cell Biology, Biochemistry, Immunology,
β-sitosterol   tlr4   nf-κb   gmi-r1   inflammation   sciatica  

β-Sitosterol Alleviates Neuropathic Pain by Inhibiting the TLR4/NF-κB Signaling Pathway Background Neuropathic pain is a common and difficult-to-treat chronic pain condition in clinical practice, with complex and not fully understood etiology. Research has shown that neuroinflammation is one of the main causes of chronic neuropathic pain. Microglia...